A programmable multivalent antiviral conjugate platform shows that attaching three copies of a neuraminidase inhibitor to an ...
A comprehensive Molecular Cancer review explains how antibody-drug conjugates deliver lethal payloads to tumors, why ...
Callio Therapeutics (“Callio” or “the Company”), a global, clinical-stage biotechnology company advancing dual-payload antibody-drug conjugates (ADCs) as the next frontier of rationally designed ...
Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of essential cell functions. It is therefore important to block the activity of ...
With peptide conjugate therapies achieving blockbuster sales and around 300 peptide-drug conjugates having entered clinical development, interest is expanding across new conjugate types and ...
Scarce end-to-end ADC capacity supports premium pricing, while outsourcing, oncology pipelines and Asia-Pacific expansion create strategic growth opportunities.Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) - ...
Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data The present article reviews the current evidence ...
Treatment Tolerability in Older Adults With Advanced Cancer Receiving Geriatric Assessment–Guided Versus Oncologist-Guided Primary Treatment Modification: Secondary Analysis of the GAP70+ Trial For ...
In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports. In the recent years, antibody-drug conjugates (ADC) have been gradually gaining ...
Lonza's Visp facility serves as its manufacturing headquarters for its antibody-drug conjugate offerings. (Lonza) (Lonza ) The search for next-gen oncology therapies has sparked an arms race in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results